Samsung Bio Affiliates Secure Major Global Pharmaceutical Contracts

Samsung Bioepis has entered into a partnership agreement with Teva Pharmaceuticals International GmbH to commercialize two biosimilars in the United States. The deal, valued at up to 420 million USD (approximately 563.2 billion KRW), covers the infliximab biosimilar Renflexis (SB2) and the etanercept biosimilar Eticovo (SB4), both of which have received FDA approval. Under the agreement, Samsung Bioepis will manage development, production, and supply, while Teva will handle U.S. sales. The contract includes an upfront payment of up to 75 million USD and potential milestones totaling 345 million USD based on launch and sales targets.

Separately, Samsung Biologics announced a new contract manufacturing agreement with a global pharmaceutical company worth approximately 324.8 million USD (434.3 billion KRW). This long-term contract is set to run until December 31, 2031. This latest deal brings Samsung Biologics' cumulative orders since its founding to over 22.3 billion USD. While the specific client and products remain confidential due to non-disclosure agreements, the contract supports the company's strategy to expand production capacity and diversify its portfolio, including antibody-drug conjugates and peptides.